Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 5, 2016, Pages 796-801

  Sher, Taimur ^a   Dispenzieri, Angela ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

AL amyloidosis; Hematopoeitic stem cell transplantation; Immunoglobulin light chain amyloidosis; Stem cell transplantation

Indexed keywords

ADULT; AMYLOIDOSIS; CASE REPORT; FEASIBILITY STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; MALE; MIDDLE AGED; PATIENT SAFETY; PATIENT SELECTION; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; BLOOD; HISTORY; PROCEDURES; TRENDS;

IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED;

EID: 84951169726     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.10.010     Document Type: Review

References (31)

1. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995, 32:45-59.
2. Palladini G., Perfetti V., Obici L., et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004, 103:2936-2938.
3. Gertz M.A., Kyle R.A. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Int Med 1990, 150:629-633.
4. Comenzo R.L., Vosburgh E., Simms R.W., et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996, 88:2801-2806.
5. Comenzo R.L., Vosburgh E., Falk R.H., et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998, 91:3662-3670.
6. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002, 113:549-555.
7. Moreau P., Leblond V., Bourquelot P., et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998, 101:766-769.
8. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Eng J Med 2007, 357:1083-1093.
9. Migrino R.Q., Mareedu R.K., Eastwood D., et al. Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr 2009, 22:1396-1402.
10. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant 2011, 46:970-975.
11. Tsai S.B., Seldin D.C., Quillen K., et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood 2012, 120:4445-4446.
12. Dispenzieri A., Gertz M.A., Kyle R.A., et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004, 22:3751-3757.
13. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma 2010, 51:2181-2187.
14. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007, 92:1415-1418.
15. Girnius S., Seldin D.C., Skinner M., et al. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Ann Hematol 2010, 89:579-584.
16. Dispenzieri A., Lacy M.Q., Katzmann J.A., et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006, 107:3378-3383.
17. Kumar S., Dispenzieri A., Lacy M.Q., et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012, 30:989-995.
18. Johnston P.B., Lacy M.Q., Dispenzieri A., et al. Toxicities associated with stem cell mobilization utilizing cyclophosphamide and grown factor versus G-CSF alone in primary systemic amyloidosis. Blood 2000, 96:182a. [abstract].
19. Leung N., Leung T.R., Cha S.S., et al. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005, 106:3353-3357.
20. Kumar S., Dispenzieri A., Lacy M.Q., et al. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001, 28:381-385.
21. Hoshino Y., Hatake K., Muroi K., et al. Bleeding tendency caused by the deposit of amyloid substance in the perivascular region. Intern Med 1993, 32:879-881.
22. Choufani E.B., Sanchorawala V., Ernst T., et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001, 97:1885-1887.
23. Falk R.H., Rubinow A., Cohen A.S. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 1984, 3:107-113.
24. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004, 103:3960-3963.
25. Kumar S., Gertz M., Lacy M., et al. Recent improvements in survival in light chain amyloidosis and the importance of an early mortality risk score. Blood 2010, 19:116-121.
26. Dubrey S.W., Burke M.M., Hawkins P.N., Banner N.R. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004, 23:1142-1153.
27. Gillmore J.D., Goodman H.J., Lachmann H.J., et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006, 107:1227-1229.
28. Mikhael J.R., Schuster S.R., Jimenez-Zepeda V.H., et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012, 119:4391-4394.
29. Sanchorawala V., Quillen K., Sloan J.M., et al. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica 2011, 96:1890-1892.
30. Landau H., Hassoun H., Bello C., et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 2011, 18(Suppl 1):130-131.
31. Warsame R., Bang S.M., Kumar S.K., et al. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. Eur J Haematol 2014, 92:485-490.